Abstract: Pharmaceutical compositions are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
Type:
Application
Filed:
May 21, 2004
Publication date:
November 4, 2004
Applicants:
Pfizer, Inc., Pfizer Products, Inc.
Inventors:
Jotham Wadsworth Coe, Steven Bradley Sands, Edmund Patrick Harrigan, Brian Thomas O'Neill, Eric Jacob Watsky
Abstract: The present invention relates to polynucleotides associated with angiogenesis-related disorders. The present invention also relates to canine endostatin genes, novel genes associated with angiogenesis-related disorders, such as cancer. The invention encompasses endostatin nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, endostatin gene products and antibodies directed against such gene products, cloning vectors containing mammalian endostatin gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of endostatin genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders, e.g., cancer. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, e.g.
Abstract: Four antigenic preparations are provided, each of which contains a different protein from Leptospira which can be used immunologically in vaccines for leptospirosis caused by this organism. Also provided in the invention are polynucleotides encoding these four proteins and antibodies which bind the proteins for use in the diagnosis of leptospirosis.
Type:
Grant
Filed:
September 25, 2002
Date of Patent:
October 5, 2004
Assignees:
Pfizer Inc., Pfizer Products Inc.
Inventors:
Eric A. Utt, Michael Stephen Willy, Don A. Dearwester
Abstract: The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
Type:
Application
Filed:
April 9, 2004
Publication date:
September 30, 2004
Applicants:
Pfizer, Inc., Pfizer Products, Inc.
Inventors:
Bertrand L. Chenard, Frank S. Menniti, Mario D. Saltarelli
Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
Abstract: A drug delivery device for delivering hormonal and other veterinary treatments intra-vaginally. A substance dispenser (21) is separate from the supporting device (20). The dispenser is in the form of drug impregnated gills or vanes (6, 7). In other aspects the drug may be dispensed by a micro-pump in the supporting device or the drug may be coated on the dispenser.
Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
Type:
Application
Filed:
January 5, 2004
Publication date:
July 29, 2004
Applicants:
Pfizer, Inc., Pfizer Products, Inc.
Inventors:
Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
Abstract: This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′
intermediates of the NHE-1 inhibitors and a new almost colorless form of the NHE-1 inhibitor N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine.
Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
Type:
Grant
Filed:
March 13, 2003
Date of Patent:
May 11, 2004
Assignees:
Pfizer, Inc., Pfizer Products, Inc.
Inventors:
David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
Type:
Application
Filed:
June 10, 2003
Publication date:
April 15, 2004
Applicants:
PFIZER PRODUCTS INC., OSI PHARMACEUTICALS, INC.
Inventors:
Penelope Elizabeth Miller, James Dale Moyer
Abstract: The present invention relates to compounds of the formula I,
wherein Z1, Z2, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and gastrointestinal disorders.
Abstract: The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.
Type:
Grant
Filed:
October 14, 1999
Date of Patent:
March 30, 2004
Assignees:
Pfizer Inc., Pfizer Products Inc.
Inventors:
Robert G. Ankenbauer, Mary Jo Baarsch, Manuel Campos, Robin Keich, Everett Rosey, Brian Suiter, Lynn Warren-Stewart
Abstract: The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.
Abstract: The present invention is directed to a process for the preparation of the mesylate trihydrate of the (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol compound having the formula (I):
The present invention is also further comprises a process for enantiomeric resolution and isolation of the (D)-(−)-tartrate salt of the compound of the formula (I).
Type:
Grant
Filed:
April 23, 2001
Date of Patent:
November 11, 2003
Assignee:
Pfizer Products, Inc.
Inventors:
Stanley Walter Walinsky, Terry Gene Sinay, Jr., Joseph Philip Rainville
Abstract: The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1/MAG1 promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
Type:
Application
Filed:
April 21, 2003
Publication date:
September 25, 2003
Applicants:
Pfizer, Inc., Pfizer Products, Inc.
Inventors:
B. Rajendra Krishnan, Rebecca Madura, Christine Yoder, Becky Durtschi, David A. Brake
Abstract: The present invention relates to a transcription regulatory region of a myostatin gene. In particular, the invention relates to a 2.5 kb polynucleotide immediately 5′ to the myostatin coding sequence, its nucleotide sequence and methods of using this regulatory region, and fragments thereof. The present invention relates to the use of the myostatin promoter of the present invention to direct expression of a target gene in a tissue specific manner, i.e. muscle tissue. The present invention relates to the use of the myostatin promoter of the present invention in high throughput screens to identify test compounds which inhibit myostatin promoter activity or myostatin expression.
Abstract: The following invention relates to a process for oxidizing alkyl groups attached directly or via a linker, to a sulfonamide moiety (II) by the use of cytochrome P450 enzymes, to give the corresponding alcohol or carboxylic acid (I).
wherein R is an organic radical, X is a linker, Y is —C(CH3)2— or —CH(CH3)— and Z is —CH2OH or —COOH.
Abstract: Isolated polynucleotide molecules contain a nucleotide sequence that encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic compositions and assays are described.